GlassScriptPhysician profile
Steven J Jacobs
NPI 1750455259
$6,285.95
in general payments reported to CMS, 2019-2025
41 companies · $1,255 in 2025
The $1,255 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $734 · 2020: $167 · 2021: $901 · 2022: $814 · 2023: $1,435 · 2024: $979 · 2025: $1,255.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,669.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,682.80 | 2019-2025 | Tezspire, Repatha, Otezla |
| Glaxosmithkline, LLC. | $598.34 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $584.38 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $511.62 | 2019-2025 | Ofev, Jardiance, Spiriva Respimat |
| Pfizer INC. | $381.87 | 2019-2025 | |
| Bausch Health US, LLC | $263.24 | 2019-2024 | Aplenzin, Wellbutrin |
| Mylan Specialty L.P. | $259.23 | 2021-2024 | Yupelri |
| Lilly USA, LLC | $215.90 | 2021-2025 | Mounjaro, Zepbound |
| Janssen Pharmaceuticals, INC | $147.49 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $123.28 | 2019-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $118.19 | 2025 | Tezspire, Fasenra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $116.24 | 2022-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $113.73 | 2025 | |
| Mallinckrodt Hospital Products INC. | $91.74 | 2021-2023 | Acthar |
| Jazz Pharmaceuticals INC. | $88.52 | 2023-2025 | Xywav |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $83.54 | 2022-2025 | Tyvaso, Tyvaso |
| Viatris Specialty LLC | $80.09 | 2025 | Yupelri |
| E.R. Squibb & Sons, L.L.C. | $68.10 | 2019-2021 | |
| Electromed, INC. | $59.32 | 2023-2025 | Smartvest |
| Alexion Pharmaceuticals, INC. | $57.45 | 2021 | |
| Exact Sciences Corporation | $51.82 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $51.57 | 2019-2023 | |
| Heartflow, INC. | $47.55 | 2023-2025 | Ffrct |
| Alnylam Pharmaceuticals INC. | $47.04 | 2023 | Amvuttra |
| Baxter Healthcare | $45.62 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Axsome Therapeutics, INC. | $41.52 | 2023-2024 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $41.51 | 2021-2022 | |
| Ani Pharmaceuticals, INC. | $32.64 | 2025 | Purified Cortrophin Gel |
| Sumitomo Pharma America, INC. | $30.00 | 2025 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $25.37 | 2022 | |
| Philips North America LLC | $24.93 | 2019 | |
| Allergan, INC. | $24.61 | 2020 | |
| Esperion Therapeutics, INC. | $23.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.50 | 2025 | Trintellix |
| Grifols USA, LLC | $21.79 | 2021 | |
| Paratek Pharmaceuticals, INC. | $20.92 | 2022 | |
| Braintree Laboratories, INC. | $20.35 | 2019 | |
| Pulmonx Corporation | $20.35 | 2023 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Kowa Pharmaceuticals America, INC. | $18.31 | 2021 | |
| Gilead Sciences, INC. | $16.18 | 2019 | |
| Eisai INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.